The possibility to arrest PD advancement by inhibiting NLRP3 induced neuroinflammation has been confirmed by the administration of MCC950 in rodent PD models, which resulted in a mitigation of motor deficits and reduced accumulation of α-Syn aggregates [134]. Here, NLRP3 is linked to Parkinson disease.